Ivermectin exposures reported to the Poisons Information Helpline in South Africa during the COVID-19 pandemic.

التفاصيل البيبلوغرافية
العنوان:	Ivermectin exposures reported to the Poisons Information Helpline in South Africa during the COVID-19 pandemic.
المؤلفون:	Pillay-Fuentes Lorente V; Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. 14847795@sun.ac.za., Voigt G; Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. 14847795@sun.ac.za., Du Plessis CE; Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. 14847795@sun.ac.za., Balme K; Red Cross War Memorial Children's Hospital and Department of Paediatrics and Child Health, Faculty of Health Sciences, University of Cape Town, South Africa. 14847795@sun.ac.za., Marks CJ; Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. 14847795@sun.ac.za., Decloedt EH; Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. 14847795@sun.ac.za., Stephen C; Red Cross War Memorial Children's Hospital and Department of Paediatrics and Child Health, Faculty of Health Sciences, University of Cape Town, South Africa. 14847795@sun.ac.za., Reuter H; Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. 14847795@sun.ac.za., Van Rensburg R; Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. 14847795@sun.ac.za.
المصدر:	South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde [S Afr Med J] 2022 Aug 02; Vol. 112 (8), pp. 522-525. Date of Electronic Publication: 2022 Aug 02.
نوع المنشور:	Journal Article
اللغة:	English
بيانات الدورية:	Publisher: South African Medical Association Country of Publication: South Africa NLM ID: 0404520 Publication Model: Electronic Cited Medium: Internet ISSN: 2078-5135 (Electronic) NLM ISO Abbreviation: S Afr Med J Subsets: MEDLINE
أسماء مطبوعة:	Publication: 1998- : Cape Town : South African Medical Association Original Publication: Cape Town : Medical Association of South Africa,
مواضيع طبية MeSH:	COVID-19* , Poisons*, Antiparasitic Agents/therapeutic use ; Humans ; Ivermectin/therapeutic use ; Pandemics/prevention & control ; SARS-CoV-2 ; South Africa/epidemiology
مستخلص:	Background: Ivermectin is an antiparasitic drug that has shown in vitro activity against COVID‑19. Clinical studies supporting ivermectin for COVID‑19 prevention and treatment are conflicting, with important limitations. Public support for ivermectin is significant, with extensive off-label use despite the conflicting views on its efficacy. Ivermectin tablets and injectable formulations are not registered in South Africa for human use by the South African Health Products Regulatory Authority. The National Department of Health does not currently recommend the use of ivermectin for COVID‑19. Objectives: To describe cases of ivermectin exposure reported to the Poisons Information Helpline of the Western Cape (PIHWC) before and after publication of the drug's in vitro activity against SARS-CoV-2. Methods: In a retrospective review, ivermectin-related calls reported to the PIHWC from 1 June 2015 to 30 June 2020 (period 1) were compared with calls received from 1 July 2020 to 31 July 2021 (period 2), dichotomised according to the first publication indicating ivermectin activity against SARS-CoV-2. Results: Seventy-one cases were screened, and 65 were included for analysis; 19 cases were reported during period 1 and 46 during period 2. During period 2, 25 ivermectin cases (54.3%) were related to COVID‑19 use. Of these, 24 cases (52.2%) involved veterinary preparations, 3 (6.5%) human preparations and 19 (41.3%) unknown preparations. Fourteen cases (73.7%) during period 1 and 30 (65.2%) during period 2 were reported to be symptomatic. The most common organ systems involved were the central nervous (n=26 cases; 40.0%), gastrointestinal (n=18; 27.7%), ocular (n=9; 13.8%) and dermatological (n=5; 7.7%) systems. Conclusion: Ivermectin-related exposure calls increased during study period 2, probably as a result of ivermectin being used as preventive and definitive therapy for COVID‑19 in the absence of robust evidence on efficacy, dosing recommendations or appropriate formulations.
المشرفين على المادة:	0 (Antiparasitic Agents) 0 (Poisons) 70288-86-7 (Ivermectin)
تواريخ الأحداث:	Date Created: 20221010 Date Completed: 20221011 Latest Revision: 20221014
رمز التحديث:	20231215
DOI:	10.7196/SAMJ.2022.v112i8.16473
PMID:	36214394
قاعدة البيانات:	MEDLINE

Full Text Finder

الوصف
تدمد:	2078-5135
DOI:	10.7196/SAMJ.2022.v112i8.16473